The dual SGLT1/2 inhibitor sotagliflozin was also tested in a dedicated HF trial (SOLOIST-WHF) [19]; however, exclusively, patients with T2DM and recent hospitalization for worsening HF were enrolled. The gene discussed is SLC5A1; the disease is hydrops fetalis.